Vesalic toxic exosome therapeutic

Vesalic's lead therapeutic program is a preclinical-stage candidate designed to treat amyotrophic lateral sclerosis (ALS) and other motor neuron diseases (MND). Developed by Vesalic Limited, the therapeutic targets a systemic metabolic dysfunction that results in the production of toxic exosome cargo. These exosomes are believed to travel from the systemic circulation into the central nervous system (CNS), where they bind to and damage motor neurons. The drug is designed to intercept and neutralize these toxic exosomes before they can cause neuronal damage, potentially slowing or halting disease progression in both monogenic and sporadic forms of ALS. The company is currently conducting in vivo studies and plans to file for regulatory approval to initiate clinical trials in 2027.